Print

Purpose

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1), history of RRMM or at least 1 but not greater than 3 prior anti-myeloma treatment (PAMT) regimens (Part 2, Arms A, B, C, and D); history of quadruple class exposed RRMM having received BCMA TCE as the most recent line of therapy (Part 2, Arm E). - Measurable multiple myeloma (MM) as per International Myeloma Working Group (IMWG). - Eastern Cooperative Oncology Group performance status of 0-1. - Adherence to contraception requirements.

Exclusion Criteria

  • Prior treatment with alnuctamab (Arm A), mezigdomide (Arms B and E), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D). - Prior treatment with GPRC5D-targeting therapies as of Protocol Amendment 02 (Part 1 and Part 2). - Other protocol-defined inclusion/exclusion criteria apply.

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Arm A: BMS-986393 + Alnuctamab
  • Drug: BMS-986393
    Specified dose on specified days
    Other names:
    • CC-95266
    • Arlocabtagene autoleucel
    • arlo-cel
  • Drug: Alnuctamab
    Specified dose on specified days
    Other names:
    • BMS-986349
    • CC-93269
    • EM901
Experimental
Arm B: BMS-986393 + Mezigdomide
  • Drug: BMS-986393
    Specified dose on specified days
    Other names:
    • CC-95266
    • Arlocabtagene autoleucel
    • arlo-cel
  • Drug: Mezigdomide
    Specified dose on specified days
    Other names:
    • BMS-986348
    • CC-92480
Experimental
Arm C: BMS-986393 + Iberdomide
  • Drug: BMS-986393
    Specified dose on specified days
    Other names:
    • CC-95266
    • Arlocabtagene autoleucel
    • arlo-cel
  • Drug: Iberdomide
    Specified dose on specified days
    Other names:
    • BMS-986382
    • CC-220
Experimental
Arm D: BMS-986393 + Elranatamab
  • Drug: BMS-986393
    Specified dose on specified days
    Other names:
    • CC-95266
    • Arlocabtagene autoleucel
    • arlo-cel
  • Drug: Elranatamab
    Specified dose on specified days
    Other names:
    • Elrexfio
Experimental
Arm E: BMS-986393 + Mezigdomide and Dexamethasone
  • Drug: BMS-986393
    Specified dose on specified days
    Other names:
    • CC-95266
    • Arlocabtagene autoleucel
    • arlo-cel
  • Drug: Mezigdomide
    Specified dose on specified days
    Other names:
    • BMS-986348
    • CC-92480
  • Drug: Dexamethasone
    Specified dose on specified days
    Other names:
    • Decadron

Recruiting Locations

University of Alabama at Birmingham
Birmingham, Alabama 35294-3300
Contact:
Susan Bal, Site 0008
205-934-1908

Mayo Clinic in Arizona - Phoenix
Phoenix, Arizona 85054
Contact:
Julia Wiedmeier-Nutor, Site 0002
855-776-0015

City of Hope Comprehensive Cancer Center
Duarte, California 91010
Contact:
Myo Htut, Site 0028
626-256-4673

Mayo Clinic in Florida
Jacksonville, Florida 32224
Contact:
Sikander Ailawadhi, Site 0005
904-953-0853

Northside Hospital
Atlanta, Georgia 30342
Contact:
Scott Solomon, Site 0006
404-255-1930

Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215
Contact:
Jacalyn Rosenblatt, Site 0027
617-667-9920

Dana-Farber Cancer Institute
Boston, Massachusetts 02215
Contact:
Omar Nadeem, Site 0011
617-632-3000

Mayo Clinic in Rochester, Minnesota
Rochester, Minnesota 55905
Contact:
Taxiarchis Kourelis, Site 0001
855-776-0015

University Of Nebraska Medical Center
Omaha, Nebraska 68198
Contact:
Christopher D'Angelo, Site 0010
402-559-8110

John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey 07601-2191
Contact:
David Siegel, Site 0004
551-996-8704

Roswell Park Cancer Institute
Buffalo, New York 14263
Contact:
Ehsan Malek, Site 0007
216-286-4441

Laura and Isaac Perlmutter Cancer Center
New York, New York 10016
Contact:
Jingmei Hsu, Site 0022
646-501-4848

Memorial Sloan Kettering Cancer Center
New York, New York 10065
Contact:
Sham Mailankody, Site 0012
646-608-3712

Tennessee Oncology
Nashville, Tennessee 37203
Contact:
Jesus Berdeja, Site 0025
615-329-0570

University of Texas MD Anderson Cancer Center
Houston, Texas 77030
Contact:
Krina Patel, Site 0003
713-792-6662

More Details

Status
Recruiting
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
Clinical.Trials@bms.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.